Latest News & Features
Europe
A German Federal Court decision has given patent applicants in the life sciences field plenty to think about,
as Wolfgang Bublak and Axel Berger explain. 16 October 2013
Asia
Many of the world’s biggest selling drugs have lost exclusivity in recent years, presenting huge opportunities for generic drugs companies but, as LSIPR finds out, it doesn’t have to be a dead end for the innovators. 16 October 2013
Big Pharma
The annual International Association for the Protection of IP (AIPPI) conference in Helsinki, Finland, assessed the potential problems for pharmaceutical companies trying to brand their medicinal products. 30 September 2013
Biotechnology
With a track record of successful innovation, Munich is one of the leading lights of European biotech. LSIPR went to visit. 30 September 2013
Americas
Developing new drugs is time-consuming and expensive. DelMar Pharma researches old drugs and establishes new IP around them to streamline the process. LSIPR spoke to chief executive Jeffrey Bacha about the company’s approach. 30 September 2013
Asia
There has been much debate about whether there is a global deterioration of IP, and many commentators
would suggest that India is leading the charge. Andrew Jenner and Ernest Kawka reflect on the experiences of innovative biopharmaceutical companies in India. 31 August 2013
Big Pharma
A decision from an opposition division of the European Patent Office may have “far-reaching consequences” for US patent holders, Solveig Moré tells LSIPR. 31 August 2013
Americas
In 1990, the Human Genome Project began its quest to identify every gene in the human genome. Now, Spiral Genetics can sequence a human genome in three hours. LSIPR spoke to Spiral Genetics’ chief executive Adina Mangubat to find out how the company protects its IP. 31 August 2013
Americas
Danish firm Bavarian Nordic has a portfolio of patents for vaccines and cancer treatments, but likes to keep some of its cards close to its chest, as LSIPR finds out. 31 July 2013
Europe
At some offices, the passage of a patent through the system is not quite as fast as applicants might hope—and at others it may be quicker than they would like. Matt Smith and Jonathan Wills outline the situation. 31 July 2013